Tafasitamab Therapy Significantly Reduces Disease Progression Risks in Follicular Lymphoma Patients A recent study shows that adding Tafasitamab to standard treatments for follicular lymphoma patients significantly reduces disease progression risks by 57%.

Tafasitamab Therapy Significantly Reduces Disease Progression Risks in Follicular Lymphoma Patients #USA #San_Diego #Follicular_Lymphoma #Tafasitamab #BC_Cancer